Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Statement: Zantac (ranitidine) litigation
GSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement with Boyd/Steenvoord.
Download (PDF, 108.6KB) -
ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV
Key abstracts to be presented at CROI 2024 by ViiV Healthcare and its study partners.
Download (PDF, 318.5KB) -
GSK announces positive headline results from EAGLE-1 phase III trial for gepotidacin in uncomplicated urogenital gonorrhoea (GC)
EAGLE-1 trial met its primary efficacy endpoint.
Download (PDF, 137.7KB) -
LATITUDE phase III interim trial data indicates ViiV Healthcare’s long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) has superior efficacy compared to daily therapy in individuals living with HIV who have adherence challenges
Full data set to be presented at an upcoming scientific conference.
Download (PDF, 147.7KB) -
GSK completes acquisition of Aiolos Bio
GSK has completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company.
Download (PDF, 119.6KB) -
GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B
Designation underscores the unmet need for medicines that can achieve functional cure in patients with chronic hepatitis B (CHB)
Download (PDF, 189.2KB) -
GSK’s RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk
GSK is the first company to file for regulatory approval to extend RSV vaccination to adults aged 50-59 at increased risk.
Download (PDF, 275.7KB) -
GSK’s regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration
Shingrix already approved in China for adults aged 50 years and over.
Download (PDF, 145.0KB) -
DREAMM-7 phase III trial shows Blenrep combination nearly tripled median progression-free survival versus standard of care combination in patients with relapsed/refractory multiple myeloma
Results from an interim analysis of the DREAMM-7 phase III head-to-head trial.
Download (PDF, 184.1KB) -
Statement: Zantac (ranitidine) litigation
GSK today confirmed it has reached a confidential settlement with David Browne, resolving the case he filed in California state court.
Download (PDF, 108.6KB) -
GSK delivers strong 2023 performance and upgrades growth outlooks
FY 2023 performance highlights
Download (PDF, 942.2KB) -
GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency for the prevention of RSV disease in adults aged 50-59 at increased risk
Application supported by positive results of a Phase III study showing immune response and acceptable tolerability profile.
Download (PDF, 167.1KB) -
European Commission authorises GSK’s Omjjara (momelotinib)
First medicine in the EU specifically indicated for splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia
Download (PDF, 152.5KB) -
Nucala (mepolizumab) approved in China for use in severe asthma with an eosinophilic phenotype
Mepolizumab is the first targeted IL-5 biologic available in China as an add-on maintenance treatment for severe eosinophilic asthma.
Download (PDF, 260.3KB) -
GSK enters agreement to acquire Aiolos Bio
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody.
Download (PDF, 235.3KB) -
GSK enters exclusive license agreement with Hansoh for HS-20093
Hansoh’s HS-20093 builds on GSK’s oncology portfolio of clinical-stage antibody-drug conjugates.
Download (PDF, 182.9KB) -
Jemperli (dostarlimab) plus Zejula (niraparib) combination significantly improved progression-free survival in primary advanced or recurrent endometrial cancer in RUBY Part 2 Phase III trial
Results reinforce development approach of using Jemperli as a backbone in immuno-oncology-based combination therapies
Download (PDF, 203.3KB) -
Japan’s Ministry of Health, Labour and Welfare accepts Arexvy (RSV vaccine) regulatory application to prevent RSV disease in adults aged 50-59 at increased risk
Submission supported by positive results of a Phase III study showing immune response and safety in adults aged 50-59.
Download (PDF, 249.3KB) -
GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the first and only frontline immuno-oncology treatment in the European Union for dMMR/MSI-H primary advanced or recurrent endometrial cancer
European Commission converts previous conditional approval to full approval as monotherapy for second-line dMMR/MSI-H endometrial cancer.
Download (PDF, 195.8KB) -
New global analysis across five cities shows inequities in adult immunisation uptake, signalling need to redesign local and national policy interventions
Findings to be presented at the Global Coalition on Aging’s Silver Economy Forum 2023.
Download (PDF, 162.6KB)
